Patients: A total of 397 adult patients with T2D inadequately controlled on basal insulin with or without metformin were randomized to once-weekly Ozempic injection 0.5 mg (n=132), Ozempic injection 1 mg (n=131), or placebo (n=133)
Clinical bottom line: This sequential framework, beginning with documentation of GLP-1 RA exposure, followed by symptom assessment, procedural risk stratification, implementation of extended clear-liquid fasting, selective use of gastric ultrasonography, and reserving drug withdrawal for rigorously defined indications, harmonizes current pathophysiological understanding with the best available evidence and major society recommendations
Subsequent increases of 2.5 mg occur every four weeks as tolerated, up to a maximum of 15 mg per week
Cagrilintide may be relevant for laboratories or investigators who study: These uses apply strictly to research environments and do not constitute guidance for human or veterinary use
However, the system still has practical limits
Gao S, Ma G, Zhou L, Guan S, Zhang J